Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Fresno, California and other locations
Dates
study started
completion around

Description

Summary

COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement.

Keywords

COVID-19, Respiratory Tract Infections, Abatacept, abatacept infusion

Eligibility

Locations

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Minnesota
ID
NCT05822583
Phase
Phase 4 COVID-19 Research Study
Study Type
Interventional
Participants
Expecting 1500 study participants
Last Updated